Health, National Cancer Institute and Fo The content is solely the responsibility of represent the official views of the NIH of	the authors the Food a	and does not nece and Drug Administration	DA). essarily ation.	
Please add "yes" or "no" to each table cell. If "yes", please turn cell background color to yellow.	Tobacco Industry	E-cigarette & nicotine product industry	Pharma Industry	
The work being presented has received funding or other means of support from any of the following sources:	No	No	No	
Any of the authors have received funding (including consultancy) from any of the following sources in the past 5 years:	No	No	Yes	Annika

Objectives

- To investigate patterns of e-cigarette flavour use in people using e-cigarettes to stop smoking in intervention studies
- To estimate associations between ecigarette flavours and smoking abstinence and study product use at 6 months+

Results

- We included 25 studies (n=16,748)
- 21 studies contributed to sub-grouped meta-analyses
- 18 studies provided participants with a choice of e-• cigarette flavours
- One study (Xu 2023) randomised participants to different e-liquid flavours
- We judged 15 studies at high, 7 at low, and 3 at unclear risk of bias



Figure 1: Flavour choice over time in five studies providing options including tobacco, mint/menthol and sweet flavours



An Exploration of Flavours in Studies of **E-Cigarettes for Smoking Cessation: Secondary** Analyses of a Systematic Review with Meta-Analyses

Nicola Lindson, PhD^a; Jonathan Livingstone-Banks, PhD^a; Ailsa R Butler, DPhil^a; David T Levy, PhD^b; Theodoulou, MClinSc^a; Caitlin Notley PhD^c; Nancy A Rigotti, MD^d; Yixian Chen, PhD^e; Jamie Hartmann-Boyce, DPhil^f

Conclusions

- cigarette flavors during a quit attempt
- Sweet flavors may be preferred overall, but this may differ depending on context
- There is no clear association between the use of e-cigarette flavors and smoking cessation or longer-term e-cigarette use, possibly due to a paucity of data

Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Rando
1.2.1 Tobacco						
Bullen 2013	71	241	17	215	39.6%	3.73 [
Hajek 2019	173	356	19	342	40.3%	8.75 [5
Lee 2018	3	18	2	9	20.0%	0.75 [
Subtotal (95% CI)		615		566	100.0%	3.81 [1.
Total events	247		38			
Heterogeneity: Tau ² =	0.55; Ch	i ² = 12.	68, df = 2	(P = 0.	002); I ² =	84%
Test for overall effect	Z= 2.71	(P = 0.0	07)			
1.2.2 Choice of tobac	co, ment	hol, sw	veet			
Myers-Smith 2022	32	59	7	47	25.6%	3.64 [
Russell 2021 (1)	62	124	28	61	37.4%	1.09 [
Russell 2021 (2)	48	103	28	60	37.0%	1.00 [
Subtotal (95% CI)		286		168	100.0%	1.44 [
Total events	142		63			
Heterogeneity: Tau ² =	0.21; Ch	i² = 11.	21, df = 2	(P = 0.	004); l ² =	82%
Test for overall effect.	Z=1.22	(P = 0.2)	(2)			

Test for subgroup differences: Chi² = 2.87, df = 1 (P = 0.09), I² = 65.2% Footnotes (1) NSP EC arm; control arm split to avoid double-counting

(2) FBNP EC arm; control group split to avoid double-counting

Figure 2: Forest plot subgrouped by flavours provided for study product use outcome; e-cigarette vs. NRT comparison

- Where participants had a choice of flavours, and this was tracked over time, some switching between flavours occurred (Fig.1)
- There was an indication that sweet/fruit flavours were preferred over tobacco and menthol; however, there were differences across studies
- Subgroup analyses showed no clear associations between flavours provided and smoking cessation or study product use (e.g., Fig 2)
- One study (Xu 2023) randomised participants to two flavour conditions (tobacco vs. choice of sweet, tobacco, menthol) and found similar smoking abstinence and long-term e-cigarette use between arms at 12m

GEORGETOWN UNIVERSITY

• Some people using e-cigarettes to quit smoking switch between e-



UMassAmherst

TCORS

a Nuffield Department of Primary Care Health Sciences, University of Oxford, UK; b Georgetown University-Lombardi Comprehensive Cancer Center, USA; c Norwich Medical School, University of East Anglia, UK; d Massachusetts General Hospital, Harvard Medical School, USA; e Department of Integrative Oncology, British Columbia Cancer Research Institute, Canada; f Department of Health Promotion and Policy, University of Massachusetts Amherst

Methods

For more information contact Dr Nicola Lindson at nicola.lindson@phc.ox. ac.uk, and access the paper using the QR code

References

Bullen C, Howe C, Laugesen M, McRobbie H, Parag V, Williman J, et al. Electronic cigarettes for smoking cessation: a randomised controlled trial. The Lancet. 2013;382(9905):1629-37 Hajek P, Phillips-Waller A, Przulj D, Pesola F, Myers Smith K, Bisal N, et al. A randomized trial of ecigarettes versus nicotine-replacement therapy. New England Journal of Medicine. 2019;380(7):629-37 Lee SM, Tenney R, Wallace AW, Arjomandi M. E-cigarettes versus nicotine patches for perioperative smoking cessation: a pilot randomized trial. PeerJ. 2018;6:e5609 Lindson N, Butler AR, McRobbie H, Bullen C, Hajek P, Begh R, et al. Electronic cigarettes for smoking cessation. Cochrane Database of Systematic Reviews. 2024(1) Myers Smith K, Phillips-Waller A, Pesola F, McRobbie H, Przulj D, Orzol M, et al. E-cigarettes versus nicotine replacement treatment as harm reduction interventions for smokers who find quitting difficult: randomized controlled trial. Addiction. 2022;117(1):224-33 Russell C, McKeganey, Katsampouris E, Satchwell A, Haseen F. A randomised community-based trial of a closed-system pod e-vapour product and nicotine replacement therapy for cigarette abstinence and reduction [PH-353]. Society for Research on Nicotine and Tobacco (SRNT) 2021 Annual Meeting; Feb 24-27 2021; p. 230 Xu Y, Goldenson NI, Prakash S, Augustson EM, Shiffman S. Randomized trial assessing the effect of the JUUL system on switching away from cigarettes and smoking reduction among U.S. adults who smoke cigarettes. Exp Clin Psychopharmacol. 2024; 32(1): 3–15





Center for the Assessment of Tobacco Regulations [CAsToR]

Secondary analyses of a Cochrane living systematic review of e-cigarettes for smoking cessation (Lindson 2024)

Included studies provided adults who smoked combustible cigarettes with nicotine ecigarettes for smoking cessation and provided data on e-liquid flavour use

• Incorporated studies found up to Feb 2024

Outcomes included flavour use; smoking abstinence; abstinence from all tobacco or commercial nicotine products (excluding NRT); long-term study product use

• Risk of bias assessed using Cochrane RoB 1

Data synthesised using narrative syntheses and meta-analyses subgrouped by flavours provided, with outcomes reported as risk ratios with 95% confidence intervals



